Jyong Biotech Ltd.
MENS
$55.24
$1.182.18%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.13M | 1.37M | 1.61M | 1.67M | 1.73M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.06M | 2.35M | 2.64M | 2.72M | 2.80M |
| Operating Income | -2.06M | -2.35M | -2.64M | -2.72M | -2.80M |
| Income Before Tax | -3.02M | -3.50M | -3.98M | -4.19M | -4.40M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.02 | -3.50 | -3.98 | -4.19 | -4.40 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.02M | -3.50M | -3.98M | -4.19M | -4.40M |
| EBIT | -2.06M | -2.35M | -2.64M | -2.72M | -2.80M |
| EBITDA | -1.94M | -2.23M | -2.52M | -2.59M | -2.67M |
| EPS Basic | -0.04 | -0.05 | -0.06 | -0.06 | -0.06 |
| Normalized Basic EPS | -0.03 | -0.03 | -0.03 | -0.04 | -0.04 |
| EPS Diluted | -0.04 | -0.05 | -0.06 | -0.06 | -0.06 |
| Normalized Diluted EPS | -0.03 | -0.03 | -0.03 | -0.04 | -0.04 |
| Average Basic Shares Outstanding | 286.27M | 286.27M | 286.27M | 286.27M | 286.27M |
| Average Diluted Shares Outstanding | 286.27M | 286.27M | 286.27M | 286.27M | 286.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |